Literature DB >> 26417955

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing.

R S Gammal1, M H Court2, C E Haidar1, O F Iwuchukwu3,4, A H Gaur5, M Alvarellos6, C Guillemette7, J L Lennox8, M Whirl-Carrillo6, S S Brummel9, M J Ratain10, T E Klein6, B R Schackman11, K E Caudle1, D W Haas12.   

Abstract

The antiretroviral protease inhibitor atazanavir inhibits hepatic uridine diphosphate glucuronosyltransferase (UGT) 1A1, thereby preventing the glucuronidation and elimination of bilirubin. Resultant indirect hyperbilirubinemia with jaundice can cause premature discontinuation of atazanavir. Risk for bilirubin-related discontinuation is highest among individuals who carry two UGT1A1 decreased function alleles (UGT1A1*28 or *37). We summarize published literature that supports this association and provide recommendations for atazanavir prescribing when UGT1A1 genotype is known (updates at www.pharmgkb.org).
© 2015 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26417955      PMCID： PMC4785051          DOI： 10.1002/cpt.269

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  39 in total

1.  Identification of a defect in the UGT1A1 gene promoter and its association with hyperbilirubinemia.

Authors:  Junko Sugatani; Kasumi Yamakawa; Kouich Yoshinari; Takashi Machida; Hitoshi Takagi; Masatomo Mori; Satoru Kakizaki; Tatsuya Sueyoshi; Masahiko Negishi; Masao Miwa
Journal:  Biochem Biophys Res Commun       Date:  2002-03-29       Impact factor: 3.575

2.  Genetic factors influencing severe atazanavir-associated hyperbilirubinemia in a population with low UDP-glucuronosyltransferase 1A1*28 allele frequency.

Authors:  Wan Beom Park; Pyoeng Gyun Choe; Kyoung-Ho Song; Jae Hyun Jeon; Sang Won Park; Hong Bin Kim; Nam Joong Kim; Myoung-Don Oh; Kang Won Choe
Journal:  Clin Infect Dis       Date:  2010-07-01       Impact factor: 9.079

3.  Variability at the uridine diphosphate glucuronosyltransferase 1A1 promoter in human populations and primates.

Authors:  D Hall; G Ybazeta; G Destro-Bisol; M L Petzl-Erler; A Di Rienzo
Journal:  Pharmacogenetics       Date:  1999-10

4.  Bilirubin dependence on UGT1A1 polymorphisms, hemoglobin, fasting time and body mass index.

Authors:  Carina Rodrigues; Elísio Costa; Emília Vieira; Rosário Santos; João De Carvalho; Petronila Rocha-Pereira; Alice Santos-Silva; Elsa Bronze-da-Rocha
Journal:  Am J Med Sci       Date:  2012-02       Impact factor: 2.378

Review 5.  Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: correlation of genotype to phenotype.

Authors:  A Kadakol; S S Ghosh; B S Sappal; G Sharma; J R Chowdhury; N R Chowdhury
Journal:  Hum Mutat       Date:  2000-10       Impact factor: 4.878

6.  Prevalence of clinically relevant UGT1A alleles and haplotypes in African populations.

Authors:  Laura J Horsfall; David Zeitlyn; Ayele Tarekegn; Endashaw Bekele; Mark G Thomas; Neil Bradman; Dallas M Swallow
Journal:  Ann Hum Genet       Date:  2011-03       Impact factor: 1.670

7.  Bilirubin UDP-glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man.

Authors:  P J Bosma; J Seppen; B Goldhoorn; C Bakker; R P Oude Elferink; J R Chowdhury; N R Chowdhury; P L Jansen
Journal:  J Biol Chem       Date:  1994-07-08       Impact factor: 5.157

Review 8.  PharmGKB summary: very important pharmacogene information for UGT1A1.

Authors:  Julia M Barbarino; Cyrine E Haidar; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2014-03       Impact factor: 2.089

9.  Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.

Authors:  Jeffrey L Lennox; Raphael J Landovitz; Heather J Ribaudo; Ighovwerha Ofotokun; Lumine H Na; Catherine Godfrey; Daniel R Kuritzkes; Manish Sagar; Todd T Brown; Susan E Cohn; Grace A McComsey; Francesca Aweeka; Carl J Fichtenbaum; Rachel M Presti; Susan L Koletar; David W Haas; Kristine B Patterson; Constance A Benson; Bryan P Baugh; Randi Y Leavitt; James F Rooney; Daniel Seekins; Judith S Currier
Journal:  Ann Intern Med       Date:  2014-10-07       Impact factor: 25.391

10.  Clinical and pharmacogenetic factors affecting neonatal bilirubinemia following atazanavir treatment of mothers during pregnancy.

Authors:  Timothy Eley; Shu-Pang Huang; Francesca Conradie; Carmen D Zorrilla; Deirdre Josipovic; Mariëtte Botes; Olayemi Osiyemi; Hélène Hardy; Richard Bertz; Donnie McGrath
Journal:  AIDS Res Hum Retroviruses       Date:  2013-07-19       Impact factor: 2.205
View more
  62 in total

1.  Clinical Pharmacology & Therapeutics: Past, Present, and Future.

Authors:  S A Waldman; A Terzic
Journal:  Clin Pharmacol Ther       Date:  2017-03       Impact factor: 6.875

Review 2.  Genetic Testing in Clinical Settings.

Authors:  Nora Franceschini; Amber Frick; Jeffrey B Kopp
Journal:  Am J Kidney Dis       Date:  2018-04-11       Impact factor: 8.860

Review 3.  Biomarkers of adverse drug reactions.

Authors:  Daniel F Carr; Munir Pirmohamed
Journal:  Exp Biol Med (Maywood)       Date:  2017-09-26

Review 4.  The dawn of precision medicine in HIV: state of the art of pharmacotherapy.

Authors:  Ying Mu; Sunitha Kodidela; Yujie Wang; Santosh Kumar; Theodore J Cory
Journal:  Expert Opin Pharmacother       Date:  2018-09-20       Impact factor: 3.889

5.  Sources of Interindividual Variability.

Authors:  Yvonne S Lin; Kenneth E Thummel; Brice D Thompson; Rheem A Totah; Christi W Cho
Journal:  Methods Mol Biol       Date:  2021

6.  PharmGKB summary: atazanavir pathway, pharmacokinetics/pharmacodynamics.

Authors:  Maria Alvarellos; Chantal Guillemette; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2018-05       Impact factor: 2.089

7.  Development of a postgraduate year 2 pharmacy residency in clinical pharmacogenetics.

Authors:  Cyrine E Haidar; James M Hoffman; Roseann S Gammal; Mary V Relling; Kristine R Crews
Journal:  Am J Health Syst Pharm       Date:  2017-03-15       Impact factor: 2.637

Review 8.  Germline genetic variants with implications for disease risk and therapeutic outcomes.

Authors:  Amy L Pasternak; Kristen M Ward; Jasmine A Luzum; Vicki L Ellingrod; Daniel L Hertz
Journal:  Physiol Genomics       Date:  2017-09-08       Impact factor: 3.107

9.  Prolonged central apnoea after intravenous morphine administration in a 12-year-old male with a UGT1A1 loss-of-function polymorphism.

Authors:  Michael S Toce; Hyun Kim; Sarita Chung; Baruch S Krauss
Journal:  Br J Clin Pharmacol       Date:  2018-11-12       Impact factor: 4.335

Review 10.  The Clinical Pharmacogenetics Implementation Consortium: 10 Years Later.

Authors:  Mary V Relling; Teri E Klein; Roseann S Gammal; Michelle Whirl-Carrillo; James M Hoffman; Kelly E Caudle
Journal:  Clin Pharmacol Ther       Date:  2019-11-05       Impact factor: 6.875
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.